Examinando por Materia "Warfarin"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 2 de 2
  • Miniatura
    ÍtemAcceso abierto
    Efficacy of dabigatran versus warfarin in reducing thromboembolic complications in patients undergoing catheter ablation of atrial fibrillation
    (Universidad Privada Norbert Wiener, 2018-03-25) Caballero Carbajal, Danitza Jaquelyn; Farfán Pesantes, Romy Natalie; Gamarra Bustillos, Carlos
    The present study is a quantitative observational and retrospective systematic review, subjected to critical selection, using the Grade evaluation system to identify the degree of evidence, found in the following databases: Epistemonikos, PubMed, Elsevier, Sciencedirect, Wiley OnlineLibrary. The 10 articles systematically reviewed, 10% (n= 1/10) are meta-analysis, 20% (n=2/10) are systematic review, 10% (n=2/10) are case control, 60% ( n= 6/10) are cohort studies. The results of the evidence found, 50% (n=5/10) (18, 19, 22, 24, 25) indicate that the effectiveness of dabigatran versus warfarin to reduce thromboembolic complications in patients undergoing fibrillation catheter ablation headset are similar. 40% (n=2/10) (17, 21, 23,26) indicate that warfarin is more effective than dabigatran in reducing thromboembolic complications in patients undergoing catheter ablation of atrial fibrillation. 10% (n=1/10) (20) indicate that dabigatran is more effective than warfarin in reducing thromboembolic complications in patients undergoing catheter ablation of atrial fibrillation. It is thus concluded that dabigatran and warfarin have similar efficacy in reducing thromboembolic complications in patients undergoing catheter ablation of atrial fibrillation.
  • Miniatura
    ÍtemAcceso abierto
    Relationship between the dose of Warfarin, INR and protein S in anti-coagulant patients at Hospital III Yanahuara – EsSalud Arequipa. 2023 - 2024
    (Universidad Privada Norbert Wiener, 2023-11-05) Albornos Andrade, Christiam Efrain; Huamán Cárdenas, Victor Raul
    Warfarin anticoagulant treatment is limited to monitoring the INR, a value obtained through the Prothrombin test requested by doctors, especially for patients who have had thrombotic events for various reasons. Currently, in the Arequipa region, it is the most widely used method for pharmacological monitoring, adjusting doses to avoid adverse events for the patient. What is not evaluated is the action of this drug on other proteins involved in the hemostatic control process, such as protein S.